Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts

Matthew Spinelli

doi:10.1093/cid/ciag392

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts

2026-06-29

0

OA

AI

M

Matthew Spinelli *

M

Megan J Heise *

D

David V Glidden

J

Janet Grochowski

J

Jon Oskarsson

L

Larisa Niles-Carnes

E

Eudiah Ochieng

M

Meredith Lora

A

Amalia Aldredge

N

Nathanael Gistand

C

Chesa Cox

J

Jonathan A Colasanti

M

Monica Gandhi

L

Lauren F Collins

DOI：10.1093/cid/ciag392

Original

Original request for help

Save

Abstract

En 中文

Long-acting cabotegravir/rilpivirine supports virologic suppression among people with HIV (PWH) facing adherence challenges. In two large U.S. cohorts(n=1,070), 96% of viremic PWH achieved virologic suppression at a 4-week median. However, blips/failure were more frequent among PWH initiating with viremia, underscoring the need for careful monitoring and optimization of long-acting treatment.

Virologic Outcomes After LA ART Initiation with and without Viremia in Two Large U.S. Clinic Cohorts

Abstract

Journal

Organization

Cited Papers

Citing Papers